CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for 3D Medicines Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

3D Medicines Inc
SHANGHAI, SHA  China Ticker: 12441244
Business Summary
3D Medicines Inc is a China-based holding company mainly engaged in the research and development (R&D) and commercialization of biopharmaceuticals. The Company focuses on the discovery, development and commercialization of innovative drugs in the field of cancer chronic disease treatment, and also lays out the field of cancer pain management. The Company has built a complete set of internal R&D systems, and has covered the entire process from drug discovery, preclinical development, clinical trials, and registration. The Company's first marketed drug, Envafolimab, is a subcutaneously injected PD-L1 inhibitor for the treatment of pan-tumor types. The Company also has a number of innovative drug research and development pipelines. The Company primarily operates in the domestic Chinese market.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202312/31/2022Yes----

Industries
SIC Code Description
2836 Biological products, except diagnostic substances
8731 Commercial physical and biological research
6719 Offices of holding companies, not elsewhere classified

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Executive Chairman of the Board, Chief Executive Officer ZhaolongGong 60 6/25/2021 1/30/2018
Chief Financial Officer JingZhang 50 8/28/2020 8/28/2020
Senior Director - Quality Management YueHe 45 8/1/2019 8/1/2019
9 additional Officers and Directors records available in full report.

General Information
Number of Employees: 198 (As of 12/31/2023)
Outstanding Shares: 258,207,000 (As of 12/31/2023)
Stock Exchange: HKG


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, April 27, 2024